Enhanced Resolution to Study Synaptic Tau Pathology in Alzheimer’s Disease
Our recent study shows that combining Array Tomography with an advanced imaging technique called Two-Colour Direct Stochastic Optical Reconstruction Microscopy (dSTORM) allows for the observation of tau pathology at synapses with unprecedented detail. This approach...
Synaptic Proteins VAMP-2 and SNAP-25 as Biomarkers in Dementia with Lewy Bodies
Dementia with Lewy bodies (DLB) is one of the leading causes of dementia, yet clear biomarkers for its diagnosis and monitoring are still lacking. The Lewy bodies in the brains of people with DLB are primarily composed of accumulations of the protein α-synuclein,...
Stability of Alzheimer biomarkers in CSF
Alzheimer’s disease and its biomarkers in CSF Alzheimer’s disease is a chronic neurodegenerative disorder considered the most common cause of dementia in older people. Although clinical symptoms still form the core of diagnosis, imaging and cerebrospinal...
World Down Syndrome Day
Today, March 21, the Memory Unit and the Alzheimer Down Unit celebrate World Down Syndrome Day. Because diversity enriches, we work to achieve an inclusive and equal world for...
Concordance between amyloid markers in CSF
Amyloid peptides and tau markers in CSF Cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), such as β-amyloid 1-42 (Aβ1-42), total tau (tTau) and pTau181, have improved the management of patients with cognitive impairment. Although Aβ1-42 is...
Victor Montal defends his Doctoral Thesis
Víctor Montal Blancafort has presented today his Doctoral Thesis entitled “Complex neuroimaging changes in metabolite, cortical structures and regional vulnerabilities in the Alzheimer disease continuum“. The thesis, directed by Dr. Juan Fortea and...
Jordi Pegueroles defends his Doctoral Thesis
In January 18th 2022, Jordi Pegueroles Monllau presented his doctoral thesis entitled “The role of biomarkers in the current classification systems for Alzheimer’s Disease“. The thesis has been supervised by Dr. Juan Fortea and tutored by Dr....
GFAP in blood helps predict the evolution of frontotemporal dementia
GFAP and frontotemporal dementia Frontotemporal dementia is a heterogeneous entity with variable clinical manifestations. As a consequence, it can be confused with psychiatric diseases or other neurodegenerative diseases such as Alzheimer’s disease. Despite the...